Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598628 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management.
Blood Rev
January 2025
Centre for Haematology, Imperial College of Science, Technology and Medicine, London, UK; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Chemo- and immune therapies administered to treat haematologic malignancies frequently cause neurologic injury. The adverse events range from mild cognitive impairment and headaches to severe conditions such as seizures, stroke and encephalitis. We performed a comprehensive literature review and report the types, mechanisms, management and prevention of neuro-toxicity resulting from these therapies in subjects who develop these toxic effects.
View Article and Find Full Text PDF[Scabies as seen by the controversial Dr Jean Giraudeau de Saint-Gervais].
Rev Prat
September 2024
Service d'histoire de la médecine et d'éthique médicale, faculté de médecine, Université nationale et capodistrienne d'Athènes, Athènes, Grèce.
Decision Support Techniques for determination of the causal relationship between health problems of workers and their work activities.
Rev Bras Med Trab
September 2024
Institute of Science and Technology, UFF, Rio das Ostras, RJ, Brazil.
Reflecting on the complexity and impacts of determination of the causal relationship between health problems of workers and the exercise of their work activities, there is a need to learn about scientific articles that expose techniques to determine this type of causal relationship. There is also a need to reveal whether any article exposes multicriteria decision analysis technique. The aim is to quantify the techniques used to determine the causal relationship between health problems of workers and the exercise of their work activities.
View Article and Find Full Text PDFCorrigendum to "Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?"[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226].
Blood Rev
November 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China. Electronic address:
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?
Blood Rev
November 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China. Electronic address:
Measurable residual disease (MRD)-testing is used in many haematological cancers to estimate relapse risk and to direct therapy. Sometimes MRD-test results are used for regulatory approval. However, some people including regulators wrongfully believe results of MRD-testing are highly accurate and of proven efficacy in directing therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!